Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Business, Policy & Funding › Regulatory News & FDA Approvals › UK's NICE Recommends Roche's Rozlytrek for Solid Tumors With NTRK Fusions

UK's NICE Recommends Roche's Rozlytrek for Solid Tumors With NTRK Fusions

Jun 25, 2020
|
staff reporter

NEW YORK – The UK's National Institute for Health Care Excellence (NICE) on Thursday published a final draft guidance recommending the histology-independent use of entrectinib (Roche's Rozlytrek) through the Cancer Drugs Fund (CDF).

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Aug
24
Featured Webinar

Utility of Novel RNA-Based Tools in Oncology Drug Development

Sponsored by
Genecentric

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Aug
25
Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

Sep
10
Featured Webinar

Development of RNA-Based Predictive Response Signatures as Companion Diagnostics

Sponsored by
Genecentric

This webinar, Part 2 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will focus on the development of RNA-based companion diagnostics for oncology.

Oct
08
Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

What's Popular?

In Cancer

  1. European Commission Approves Novartis' Piqray, Fulvestrant for PIK3CA-Mutated Breast Cancer

  2. Merus, Elevation Oncology Advance Drug Candidates Targeting NRG1 Fusion-Positive Cancers

    Premium

  3. Medicare to Cover Myriad Genetics' BRACAnalysis for FDA-Approved CDx Indications

  4. Bristol Myers Squibb, Bluebird Bio Submit Application to FDA for Multiple Myeloma CAR T-Cell Therapy

  5. Salarius Pharmaceuticals Expanding Phase I/II Seclidemstat Study Beyond Ewing Sarcomas

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.